Efficacy and Safety Study of Low-Dose Ondansetron For Adjunctive Therapy In Adult Patients With Obsessive-Compulsive Disorder

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Obsessive-compulsive Disorder

In brief

This study is to assess the efficacy and safety of two doses of ondansetron (0.5 mg and 0.75 mg) relative to placebo when administered twice daily as adjunctive therapy for adult patients with Obsessive-Compulsive Disorder (OCD) who have not adequately responded to treatment with a serotonin reuptake inhibitor (SRI).

Key facts

Study ID
NCT01275248
Run by
Transcept Pharmaceuticals
People needed
130
Starts
2011-01-01
Expected to finish
2015-09-01
Last updated by the study team
2013-01-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.